Get started
Work

Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study

Year: 2026
Type: article
Study design: Clinical Trial
DOI: 10.1016/j.annonc.2026.08.006
Authors: N.B. Haas, T.B. Powles, P. Tomczak, S.H. Park, B. Venugopal, S.N. Symeonides, T. Ferguson, Y.-H. Chang, J.-L. Lee, P. Sawrycki, N. Sarwar, H. Gurney, M. Gross-Goupil, J.M. Burke, G. Doshi, J. Cornell, J.E. Burgents, R.F. Perini, T.K. Choueiri
Institutions: Abramson Cancer Center, University of Pennsylvania, Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, Barts Cancer Institute, Poznan University of Medical Sciences, Samsung Medical Center, Sungkyunkwan University, Beatson West of Scotland Cancer Centre, University of Glasgow, Institute of Genetics and Cancer, University of Edinburgh, Fiona Stanley Hospital, Taipei Veterans General Hospital, Asan Medical Center, University of Ulsan, Imperial College Healthcare NHS Trust, Macquarie University, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Rocky Mountain Cancer Centers, The US Oncology Network, Merck & Co., Inc., Rahway, NJ, USA (United States), Harvard University, Dana-Farber Cancer Institute
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7204251429
FWCI: 4.431
Cites: 7
Cited by: 1
Related to: